These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 8363754)

  • 1. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.
    Zwart G; Wolfs TF; Bookelman R; Hartman S; Bakker M; Boucher CA; Kuiken C; Goudsmit J
    AIDS; 1993 Apr; 7(4):467-74. PubMed ID: 8507412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
    Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
    Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
    Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
    AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
    Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
    AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.
    Warren RQ; Nkya WM; Shao JF; Anderson SA; Wolf H; Hendrix CW; Kanda P; Wabuke M; Boswell RN; Redfield RR
    J Clin Microbiol; 1992 Jan; 30(1):126-31. PubMed ID: 1370844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence analysis of selected regions of the env (V3 loop and gp41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains.
    Ayehunie S; Johansson B; Sönnerborg A; Zewdie DW; Britton S; Strannegård O
    Arch Virol; 1993; 128(3-4):229-39. PubMed ID: 8435043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina.
    Calarota SA; Libonatti OV
    Scand J Immunol; 2000 Sep; 52(3):292-7. PubMed ID: 10972906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping.
    Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; Markuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):139-49. PubMed ID: 9462924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals.
    Calarota S; Jansson M; Levi M; Broliden K; Libonatti O; Wigzell H; Wahren B
    AIDS Res Hum Retroviruses; 1996 May; 12(8):705-13. PubMed ID: 8744581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.